| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2005.02.147 |
| P698 | PubMed publication ID | 15809453 |
| P50 | author | Brigette Ma | Q56904555 |
| Anthony Tak-Cheung Chan | Q57615001 | ||
| Ka Fai To | Q99551275 | ||
| P2093 | author name string | Xiao Lin | |
| Michael J Millward | |||
| Edwin P Hui | |||
| Jacqueline Whang-Peng | |||
| Boon C Goh | |||
| Tsang-Wu Liu | |||
| Ruey-Long Hong | |||
| Alex Y Chang | |||
| Mow-Ming Hsu | |||
| Nadia Amellal | |||
| Matthias Mueser | |||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| carboplatin | Q415588 | ||
| cetuximab | Q420296 | ||
| P304 | page(s) | 3568-3576 | |
| P577 | publication date | 2005-04-04 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma | |
| P478 | volume | 23 |
| Q39023470 | AHNS Series - Do you know your guidelines? Principles of treatment for nasopharyngeal cancer: A review of the National Comprehensive Cancer Network guidelines |
| Q34242449 | Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma |
| Q53700212 | Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma. |
| Q55140322 | Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis. |
| Q92753216 | Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma |
| Q52633490 | Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. |
| Q59350023 | Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742) |
| Q35480110 | Apoptosis-inducing effects of cetuximab combined with radiotherapy and hypothermia on human nasopharyngeal carcinoma CNE cells |
| Q21198850 | Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review |
| Q33410822 | Cetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: preliminary results |
| Q90042888 | Cetuximab in the management of nasopharyngeal carcinoma - a narrative review |
| Q36668224 | Cetuximab in the treatment of head and neck cancer |
| Q37282841 | Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: a case report and review of literature. |
| Q40174506 | Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma |
| Q90398765 | Characteristic And Novel Therapeutic Strategies Of Nasopharyngeal Carcinoma With Synchronous Metastasis |
| Q92354811 | Chinese expert consensus on diagnosis and treatment of nasopharyngeal carcinoma: evidence from current practice and future perspectives |
| Q44580836 | Clinical observation of 73 nasopharyngeal carcinoma patients treated by helical tomotherapy: the China experience |
| Q33994022 | Clinical study of nasopharyngeal carcinoma treated by helical tomotherapy in China: 5-year outcomes |
| Q64081781 | Combination treatment with cetuximab in advanced nasopharyngeal carcinoma patients: a meta-analysis |
| Q43830356 | Comparison of narrow-band imaging and conventional nasopharyngoscopy for the screening of unaffected members of families with nasopharyngeal carcinoma |
| Q40172727 | Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy. |
| Q38196452 | Comprehensive treatment of squamous cell cancer of head and neck: Chinese expert consensus 2013. |
| Q40109785 | Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up |
| Q40072365 | Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study |
| Q36359374 | Current and emerging treatment options for nasopharyngeal carcinoma. |
| Q84978527 | Current treatment of nasopharyngeal carcinoma |
| Q26995560 | Emerging treatment options for nasopharyngeal carcinoma |
| Q31152476 | Endoscope-guided interstitial intensity-modulated brachytherapy and intracavitary brachytherapy as boost radiation for primary early T stage nasopharyngeal carcinoma |
| Q58129526 | Enhancing the immune stimulatory effects of cetuximab therapy through TLR3 signalling in Epstein-Barr virus (EBV) positive nasopharyngeal carcinoma |
| Q90348113 | Establishing M1 stage subdivisions by incorporating radiological features and Epstein-Barr virus DNA for metastatic nasopharyngeal carcinoma |
| Q44532853 | Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma |
| Q34001937 | Factors determining the survival of nasopharyngeal carcinoma with lung metastasis alone: does combined modality treatment benefit? |
| Q127953679 | Folate-Targeted pH and Redox Dual Stimulation-Responsive Nanocarrier for Codelivering of Docetaxel and TFPI-2 for Nasopharyngeal Carcinoma Therapy |
| Q37520428 | Folate-targeted star-shaped cationic copolymer co-delivering docetaxel and MMP-9 siRNA for nasopharyngeal carcinoma therapy |
| Q41684880 | Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial. |
| Q90835372 | Generation of novel affibody molecules targeting the EBV LMP2A N-terminal domain with inhibiting effects on the proliferation of nasopharyngeal carcinoma cells |
| Q34771143 | Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation |
| Q49960053 | Head and neck cancer in Hong Kong. |
| Q92996184 | IGF-1R Inhibition Suppresses Cell Proliferation and Increases Radiosensitivity in Nasopharyngeal Carcinoma Cells |
| Q35552076 | Identification of a microRNA signature associated with risk of distant metastasis in nasopharyngeal carcinoma |
| Q87899453 | Intensity-modulated radiotherapy for stage IVA/IVB nasopharyngeal carcinoma: clinical outcomes and patterns of failure in an endemic area in China |
| Q38690528 | Investigational drugs for nasopharyngeal carcinoma |
| Q36366495 | Kidney cancer: identification of novel targets for therapy |
| Q97423490 | Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen |
| Q43410813 | MRI-detected skull-base invasion: prognostic value and therapeutic implication in intensity-modulated radiotherapy treatment for nasopharyngeal carcinoma |
| Q36014988 | Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma |
| Q30846827 | Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma. |
| Q38827487 | MicroRNA-378g enhanced radiosensitivity of NPC cells partially by targeting protein tyrosine phosphatase SHP-1. |
| Q33599243 | Modeling nasopharyngeal carcinoma in three dimensions |
| Q64111527 | Molecular Targeted Therapy in the Management of Recurrent and Metastatic Nasopharyngeal Carcinoma: A Comprehensive Literature Review |
| Q38385856 | Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079). |
| Q86035551 | Nasopharyngeal carcinoma |
| Q39067689 | Nasopharyngeal carcinoma treated with bevacizumab combined with paclitaxel liposome plus cisplatin: a case report and literature review. |
| Q37705415 | Nasopharyngeal carcinoma: alternative treatment options after disease progression |
| Q36810352 | Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments |
| Q99711699 | Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma |
| Q37982126 | Novel systemic therapeutic for nasopharyngeal carcinoma. |
| Q28078860 | Occipital lymph node metastasis from nasopharyngeal carcinoma: a special case report and literature review |
| Q33898262 | Optimal management of a patient with recurrent nasopharyngeal carcinoma |
| Q33933009 | Parametric contrast-enhanced ultrasound as an early predictor of radiation-based therapeutic response for lymph node metastases of nasopharyngeal carcinoma |
| Q84072940 | Personalised medicine in nasopharyngeal cancer |
| Q33383131 | Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors |
| Q34488787 | Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342 |
| Q64110373 | Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer |
| Q33378256 | Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study |
| Q39799281 | Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response |
| Q47155578 | Prognostic Value of Molecular Markers and Implication for Molecular Targeted Therapies in Nasopharyngeal Carcinoma: An Update in an Era of New Targeted Molecules Development |
| Q36629614 | Prognostic score models for survival of nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy and chemotherapy |
| Q45751366 | Prognostic significance of expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in nasopharyngeal carcinoma. |
| Q50947118 | Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. |
| Q35860283 | Prognostic value of the primary lesion apparent diffusion coefficient (ADC) in nasopharyngeal carcinoma: a retrospective study of 541 cases |
| Q40078689 | Progression of understanding for the role of Epstein-Barr virus and management of nasopharyngeal carcinoma |
| Q41554686 | Propensity score matching analysis of a phase II study on simultaneous modulated accelerated radiation therapy using helical tomotherapy for nasopharyngeal carcinomas |
| Q37248002 | Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge |
| Q27022454 | Role of chemotherapy in nasopharyngeal carcinoma |
| Q33836444 | Suppression Of β-catenin Nuclear Translocation By CGP57380 Decelerates Poor Progression And Potentiates Radiation-Induced Apoptosis in Nasopharyngeal Carcinoma |
| Q37171008 | Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. |
| Q47729318 | Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review. |
| Q36407458 | Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma. |
| Q42766336 | T cell therapy for nasopharyngeal carcinoma. |
| Q36613969 | Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer |
| Q37959387 | Targeting tumor hypoxia in nasopharyngeal carcinoma. |
| Q90290848 | The Efficacy and Safety of Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Nasopharyngeal Carcinoma: Literature-based Meta-analyses |
| Q36545328 | The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma. |
| Q37052756 | The emerging role of cetuximab in head and neck cancer: a 2007 perspective |
| Q64052197 | The primary lesion apparent diffusion coefficient is a prognostic factor for locoregionally advanced nasopharyngeal carcinoma: a retrospective study |
| Q27016002 | Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma |
| Q36241068 | Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo |
| Q36707878 | Tolfenamic Acid Inhibits the Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma: Involvement of p38-Mediated Down-Regulation of Slug |
| Q46383461 | Toxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinoma |
| Q35117590 | Treatment of nasopharyngeal carcinoma cells with the histone-deacetylase inhibitor abexinostat: cooperative effects with cis-platin and radiotherapy on patient-derived xenografts |
| Q37230165 | Treatment outcome of cisplatin-based concurrent chemoradiotherapy in the patients with locally advanced nasopharyngeal cancer |
| Q33579689 | Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy |
| Q39332899 | Wogonin induces cross-regulation between autophagy and apoptosis via a variety of Akt pathway in human nasopharyngeal carcinoma cells |
Search more.